dodecyldimethylammonioethanesulfonate | 24020-67-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: dodecyldimethylammonioethanesulfonate
• 英文别名: N-dodecyl-N,N-dimethyl-2-ammonio-1-ethanesulfonate；2-(Dimethyl)-dodecyl-ammonio-ethansulfonat；2-Dodecyldimethylammonio-aethan-sulfonsaeure-(1)-betain, Dodecyldimethyltaurin betain；lauryl dimethyl sulfoethyl betaine；2-(N,N-dimethyldodecylammonio)ethanesulfonate；2-[dodecyl(dimethyl)azaniumyl]ethanesulfonate
• CAS: 24020-67-5
• 化学式: C₁₆H₃₅NO₃S
• 分子量: 321.525
• InChiKey: JMUAAHMVRDWJPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  21
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  65.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-十二烷基甲胺 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 60.0h， 生成 dodecyldimethylammonioethanesulfonate
  参考文献：
  名称：

  [EN] AMINO- OR AMMONIUM-CONTAINING SULFONIC ACID, PHOSPHONIC ACID AND CARBOXYLIC ACID DERIVATIVES AND THEIR MEDICAL USE
  [FR] DÉRIVÉS D'ACIDE SULFONIQUE, D'ACIDE PHOSPHONIQUE ET D'ACIDE CARBONIQUE CONTENANT UN GROUPE AMINO OU AMMONIUM ET LEUR UTILISATION MÉDICALE

  摘要：

  本发明涉及氨基或铵基含有磺酸、膦酸和羧酸衍生物，特别是式1、2、3、4、5或6的化合物，以及它们在医学上的用途，包括它们在治疗、预防或改善炎症、自身免疫和/或过敏性疾病中的用途。

  公开号：

  WO2012160187A1

文献信息

• Synthesis of Quaternary Alkylammonium Sulfobetaines
  作者：Robert S. Ward、Joanna Davies、Geoffrey Hodges、David W. Roberts

  DOI：10.1055/s-2002-35215

  日期：——

  A series of quaternary alkylammonium sulfobetaines of general formula RN+(CH3)2(CH2)nSO3 -, where n = 2-4, have been synthesised by reacting the corresponding N,N-dimethylamines with either sodium 2-chloroethanesulfonate (n = 2), 1,3-propanesultone (n = 3), or 1,4-butanesultone (n = 4). Full details of the preparation of the required N,N-dimethylamines are reported.

  一系列四级烷基铵阳离子硫苯甲酸盐，通用公式为 RN+(CH3)2(CH2)nSO3−，其中 n = 2-4，通过将相应的 N,N-二甲基胺与氯乙烷磺酸钠（n = 2）、1,3-丙烷磺内酯（n = 3）或 1,4-丁烷磺内酯（n = 4）反应合成。有关所需 N,N-二甲基胺的制备的完整细节已报告。
• AMINO- OR AMMONIUM-CONTAINING SULFONIC ACID, PHOSPHONIC ACID AND CARBOXYLIC ACID DERIVATIVES AND THEIR MEDICAL USE
  申请人：Schlechtingen Georg

  公开号：US20160016981A1

  公开（公告）日：2016-01-21

  The present invention relates to amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives, in particular the compounds of formula 1, 2, 3, 4, 5 or 6, and their medical use, including their use in the treatment, prevention or amelioration of an inflammatory, autoimmune and/or allergic disorder.

  本发明涉及含有氨基或铵基的磺酸、膦酸和羧酸衍生物，特别是公式1、2、3、4、5或6的化合物，以及它们在医学上的用途，包括在治疗、预防或改善炎症、自身免疫和/或过敏性疾病中的使用。
• Antigenic composition useful as a vaccine or vaccine intermediate, and process for preparing same
  申请人：New York Blood Center, Inc.

  公开号：EP0005864A1

  公开（公告）日：1979-12-12

  An antigenic composition, useful as a vaccine or vaccine intermediate, comprising a subparticulate mass containing hepatitis B surface and hepatitis B e antigens which have a particle size less than 20 nm, especially less than 5 nm, is obtained by contacting an antigenic mass containing parti- cles of HBzAg of a particle size of at least 20 nm with a detergent followed by treating the detergent-containing antigenic composition with an aqueous aldehyde solution.

  一种可用作疫苗或疫苗中间体的抗原组合物，含有乙型肝炎表面抗原和乙型肝炎e抗原的亚颗粒，其粒径小于20纳米，特别是小于5纳米，其获得方法是将含有粒径至少为20纳米的HBzAg部分的抗原块与洗涤剂接触，然后用醛水溶液处理含洗涤剂的抗原组合物。
• PROCESS FOR PRODUCING PLASMINOGEN-CONTAINING COMPOSITION
  申请人：THE GREEN CROSS CORPORATION

  公开号：EP0638314A1

  公开（公告）日：1995-02-15

  A process for producing a pharmaceutically safer plasminogen-containing composition by efficiently deactivating contaminant viruses while minimizing the loss of plasminogenic activity. The process comprises treating a plasminogen-containing composition which is likely to be contaminated by viruses with a trialkyl phosphate in solution and eliminating the phosphate. Preferably the phosphate treatment is conducted under a weakly acidic condition. The elimination of the phosphate is followed by freeze drying and heat treatment in a dried state.

  一种生产更安全的含纤溶酶原组合物的工艺，它能有效地使污染病毒失活，同时最大限度地减少纤溶酶原活性的损失。该工艺包括用三烷基磷酸酯溶液处理可能被病毒污染的含纤溶酶原组合物，并消除磷酸酯。磷酸盐处理最好在弱酸性条件下进行。除去磷酸盐后，在干燥状态下进行冷冻干燥和热处理。
• Room temperature storable immunoglobulin preparation for intravenous injection
  申请人：YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.

  公开号：EP0911037A1

  公开（公告）日：1999-04-28

  A method for producing an immunoglobulin preparation for intravenous injection, which comprises the steps of: fractionating an immunoglobulin-containing solution with 4 to 10 w/v% of polyethylene glycol having a molecular weight of from 1,000 to 10,000, at a pH value of from 4.5 to 6.5, an ionic strength of from 0.0001 to 0.1 M and a temperature of from 0 to 4°C to recover a supernatant fraction; and concentrating the supernatant fraction at a pH of from 3.5 to 5.0.

  一种生产静脉注射用免疫球蛋白制剂的方法，包括以下步骤：在 pH 值为 4.5 至 6.5、离子强度为 0.0001 至 0.1 M 和温度为 0 至 4°C 的条件下，用分子量为 1,000 至 10,000 的聚乙二醇将含免疫球蛋白的溶液分馏，回收上清液馏分；在 pH 值为 4.5 至 6.5、离子强度为 0.0001 至 0.1 M 和温度为 0 至 4°C 的条件下浓缩上清液馏分。5至6.5、离子强度为0.0001至0.1M、温度为0至4℃的条件下，分馏含免疫球蛋白的溶液，回收上清液部分；并在pH值为3.5至5.0的条件下浓缩上清液部分。